30 results
DEFM14A
AMTI
Applied Molecular Transport Inc.
21 Nov 23
Proxy related to merger
9:16am
for the treatment of ulcerative colitis (“UC”), chronic pouchitis and rheumatoid arthritis (“RA”). AMTI conducted a broad Phase 2 clinical program for AMT-101 … therapy in biologic naïve patients with moderately to severely active UC, and the FILLMORE trial as a monotherapy in patients with chronic antibiotic
8-K
EX-99.1
AMTI
Applied Molecular Transport Inc.
22 Dec 22
Other Events
5:20pm
partnership options to advance AMT-101 into Phase 3 in patients with chronic pouchitis
- Strong cash position of $76M reported in Q3 2022
SOUTH SAN … by the positive data generated with AMT-101 in chronic pouchitis, which has been granted Orphan Drug Designation in this indication. We will be seeking a partner
8-K
EX-99.1
AMTI
Applied Molecular Transport Inc.
7 Nov 22
Applied Molecular Transport Reports Third Quarter 2022 Financial Results and Provides Corporate Update
4:07pm
meeting with FDA to discuss advancing oral AMT-101 monotherapy to Phase 3 in chronic pouchitis, an orphan indication with no FDA-approved products … on the positive top-line data from our FILLMORE monotherapy trial in patients with chronic pouchitis, was an important milestone for the company” said Tahir
8-K
EX-99.1
mtsov1m3 w11740q
4 Aug 22
Applied Molecular Transport Reports Second Quarter 2022 Financial Results and Provides Corporate Update
4:10pm
8-K
EX-99.1
7zoww
6 Jul 22
Other Events
8:01am
8-K
EX-99.1
uwd7ma6r1
18 May 22
Applied Molecular Transport Provides Strategy Update
8:18am
8-K
EX-99.1
2al in6u6aakk46fmrc
9 May 22
Applied Molecular Transport Reports First Quarter 2022 Financial Results and Provides Corporate Update
4:07pm
8-K
EX-99.1
w1d6qu
25 Apr 22
Applied Molecular Transport Announces Positive Top-line Phase 2 Results from FILLMORE
8:01am
8-K
l16j7tl6cxk jyygsltb
25 Apr 22
Applied Molecular Transport Announces Positive Top-line Phase 2 Results from FILLMORE
8:01am
424B5
hh9 ozz0y
28 Mar 22
Prospectus supplement for primary offering
9:27pm
S-3
x3gkatab
11 Mar 22
Shelf registration
5:03pm
8-K
EX-99.1
gsl84t0e7dv t4u9p7s
24 Feb 22
Applied Molecular Transport Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
4:06pm
8-K
EX-99.1
5xdele m8rhtgyg
10 Nov 21
Applied Molecular Transport Reports Third Quarter 2021 Financial Results and Provides Corporate Update
4:11pm
8-K
EX-99.1
mp47k hveaqrbv72hoh2
10 Aug 21
Applied Molecular Transport Reports Second Quarter 2021 Financial Results and Provides Corporate Update
4:05pm